USE AND RESULTS OF A CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN WOMEN HPV+ AND/OR ABNORMAL PAP SMEAR ATTENDED IN A REGIONAL SPANISH HOSPITAL. PRELIMINARY ANALYSIS

P-242

Author:
Clara Gajino Suárez. Hospital Materno Infantil Teresa Herrera, Ginecology and Obstetrics, A Coruña, Spain.

SERVIZO GALEGO de SAÚDE | Complexo Hospitalario Universitario A Coruña A Coruña

Objective

A Coriolus versicolor-based vaginal gel (Papilocare®) is recently available in Spain to prevent and treat the HPV-dependent low-grade cervical lesions. Recommended dose: 1 cannula/day for 1 month + 1 cannula/alternate days for 5 months (except menstrual days).

To analyze how Papilocare® is being used in our hospital and to evaluate the treatment results in our patients.

Methods

A retrospective, observational study. Medical records of patients who completed 3 or 6 months treatment period during 2017 were analyzed. Baseline characteristics of Papilocare® users were described.

Pre and post treatment number of patients with ASCUS/LSIL, positive-HPV and high risk positive HPV were assessed.

Results

A total of 86 medical records were analyzed. Most of them (84%) were treated for 6 months. Mean age was 38.4 years (from 18 to 72 years), 43.5% were vaccinated before treatment with Papilocare®, 32,5% were smokers and 42% used condoms regularly in all their sexual relationships. Baseline pap smear: Normal 11(13%), ASCUS 3 (3.5%), LSIL 65 (75.5%) and HSIL 7 (8%). HPV test was performed in 68 patients of which 57 (89%) were high-risk HPV.

Results after treatment are shown in figures

- HPV clearance at 6 months in the total group -



- Pap smear normalization at 6 months -



- HPV clearance at 6 months in the High-Risk genotype population -



RESULTS AT 6 MONTHS BY AGE GROUP◊

SUB GROUP 25-34 YEARS OLD

- Pap smear normalization -



- HPV clearance -



◊There were 3 LSIL patients < 25 years old.

SUB GROUP 35-45 YEARS OLD

- Pap smear normalization -



- HPV clearance -



SUB GROUP > 45 YEARS OLD

- Pap smear normalization -



- HPV clearance -



Conclusions

In our hospital, most of patients using Papilocare® had LSIL. In this preliminary analysis, significant reductions of patients with pap smear alterations and significant High-Risk HPV clearance were observed after 3-6 months of Papilocare® application. The treatment with Papilocare® manages to solve the medical situation in almost 1 out of 2 women treated, avoiding more aggressive treatments such as destructive and/or excisional therapies and with no side effects reported.

IPVC 2018 32nd INTERNATIONAL PAPILLOMAVIRUS CONFERENCE in conjunction with AOGIN 2018
October 2-6, 2018 Sidney, Australia
Towards Global Control of HPV Disease